AKT1 and leukemia: IMATINIB, a tyrosine kinase inhibitor, targets c-KIT and disrupts downstream MAPK and AKT signaling pathways essential for leukemic cell survival and proliferation, making it a promising therapeutic candidate for leukemia [107].